GlassScriptPhysician profile
James Nathaniel Mason
NPI 1114362001
$1,308.50
in general payments reported to CMS, 2019-2025
14 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.46 · 2020: $105 · 2021: $117 · 2022: $127 · 2023: $524 · 2024: $201 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.95 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $421.68 | 2021-2024 | Tecvayli, Darzalex, Carvykti |
| Incyte Corporation | $300.85 | 2022-2023 | Monjuvi, Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $105.81 | 2025 | Iclusig |
| Glaxosmithkline, LLC. | $104.63 | 2020 | |
| Genmab U.S., INC. | $101.83 | 2024 | Epkinly |
| Astellas Pharma US INC | $101.32 | 2023 | Xospata |
| Astrazeneca Pharmaceuticals LP | $77.63 | 2025 | |
| Lilly USA, LLC | $43.50 | 2021 | |
| Celgene Corporation | $18.38 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.79 | 2025 | Libtayo |
| Jazz Pharmaceuticals INC. | $16.08 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.